|
|
|
| INTERPHEX is back in New York with exciting show features. This includes a BRAND-NEW Conference Program! The INTERPHEX Conference will unfold in the Learning Lab on the Exhibit Hall floor of INTERPHEX. It will feature peer-reviewed scientific presentations that examine quality systems, contamination control strategies for cell and gene therapies, 3D bioprinting, AI applications for formulations, and U.S. FDA regulatory updates, among other hot industry topics. Register today. |
|
|
|
|
By Liz Oestreich, Kalah Auchincloss, and Madeleine Giaquinto, Greenleaf Health | The U.S. FDA issued 180 warning letters to drug and biologics manufacturers in fiscal year 2023 (FY23), and 94 of them were based on an on-site inspection of the company. This article provides an analysis of trends and observations from the inspection-based letters, as well as additional insight into the agency’s approach to enforcement. |
|
|
|
| 4 Factors To Consider When Scaling Up | Article | By Josh Russell, AST | It's essential to understand how scaling up affects your aseptic filling operations. Here are four topics to consider to help ensure your drug product will be taken care of and ready for production. |
|
|
| Placing Patients At The Center Of Drug Design | Q&A | Catalent | Experts discuss the best time to start thinking about patient centricity, the steps developers can take to achieve patient-centric drug design, and how formulation and dosage forms can make a difference. |
|
|
|
| A Globally Unique Capability For Nanoforming HPAPIs | Article | By Dr. David Rowe and Antonio da Silva, Nanoform | As demand for high-potency active pharmaceutical ingredients (HPAPIs) rises, ensuring your company utilizes specialized facilities with HPAPI handling capabilities is crucial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SimpliFiH Solutions For Accelerated Pharmaceutical Development | Article | By David K. Lyon, Ph.D., and Conrad Roten, Ph.D., Lonza | Explore an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability. |
|
|
|
|
|
|
|
|
|
Connect With Pharmaceutical Online: |
|
|
|